A role for procarboxypepidase U (TAFI) in thrombosis.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Frontiers in Bioscience

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2741/2203PMID 17127436
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Measurement of procarboxypeptidase U (TAFI) in human plasma: a laboratory challenge.

  2006influential reference
• Thrombin-activatable fibrinolysis inhibitor aka procarboxypeptidase U

  2006cited by this paper
• Murine model of ferric chloride‐induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor

  2006cited by this paper
• Discovery of thrombin activatable fibrinolysis inhibitor (TAFI)

  2006cited by this paper
• Limited mutagenesis increases the stability of human carboxypeptidase U (TAFIa) and demonstrates the importance of CPU stability over proCPU concentration in down‐regulating fibrinolysis

  2006cited by this paper
• Thrombin activatable fibrinolysis inhibitor (TAFI) polymorphisms and plasmaTAFI levels measured with an ELISA insensitive to isoforms in patients with venous thromboembolic disease (VTD)

  2006cited by this paper
• Development of a fast kinetic method for the determination of carboxypeptidase U (TAFIa) using C-terminal arginine containing peptides as substrate.

  2005cited by this paper
• Molecular mechanisms of fibrinolysis

  2005cited by this paper
• TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study

  2005cited by this paper
• Carboxypeptidase U (TAFIa): a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease

  2005cited by this paper
• Demonstration of enhanced endogenous fibrinolysis in thrombin activatable fibrinolysis inhibitor-deficient mice

  2005cited by this paper
• Development of ELISAs Measuring the Extent of TAFI Activation

  2005cited by this paper
• LETTERS TO THE EDITOR: Fast kinetic assay for the determination of procarboxypeptidase U (TAFI) in human plasma

  2005cited by this paper
• Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis.

  2005cited by this paper
• Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact

  2005cited by this paper
• High functional levels of thrombin‐activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke

  2005cited by this paper
• Factor XII‐dependent increases in thrombin activity induce carboxypeptidase‐mediated attenuation of pharmacological fibrinolysis

  2004cited by this paper
• TAFI polymorphisms at amino acids 147 and 325 are not risk factors for cerebral infarction

  2004cited by this paper
• Activated Thrombin-activatable Fibrinolysis Inhibitor Reduces the Ability of High Molecular Weight Fibrin Degradation Products to Protect Plasmin from Antiplasmin*

  2004cited by this paper
• Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism.

  2004cited by this paper
• Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism.

  2004cited by this paper
• Generation and Characterization of a Highly Stable Form of Activated Thrombin-activable Fibrinolysis Inhibitor*

  2004cited by this paper
• The Intrinsic Threshold of the Fibrinolytic System Is Modulated by Basic Carboxypeptidases, but the Magnitude of the Antifibrinolytic Effect of Activated Thrombin-activable Fibrinolysis Inhibitor Is Masked by Its Instability*

  2004cited by this paper
• A Study of the Protection of Plasmin from Antiplasmin Inhibition within an Intact Fibrin Clot during the Course of Clot Lysis*

  2004cited by this paper
• Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level.

  2004cited by this paper
• Enhancement of Fibrinolysis by EF6265 [(S)-7-Amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino)propyl]hydroxyphosphinoyl] methyl]heptanoic Acid], a Specific Inhibitor of Plasma Carboxypeptidase B

  2004cited by this paper
• TAFI: a promising drug target?

  2004cited by this paper
• A functional single nucleotide polymorphism in the thrombin‐activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease

  2004cited by this paper
• A functional assay for measuring activated thrombin-activatable fibrinolysis inhibitor in plasma.

  2004cited by this paper
• Thrombin-activatable fibrinolysis inhibitor.

  2004cited by this paper
• Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold‐dependent mechanism

  2004influential reference
• Stabilization Versus Inhibition of TAFIa by Competitive Inhibitors in Vitro *

  2003influential reference
• Thrombin-Activable Fibrinolysis Inhibitor Levels in the Acute Phase of Ischemic Stroke

  2003cited by this paper
• Novel thrombolytic agents for treatment of acute myocardial infarction

  2003cited by this paper
• Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets.

  2003cited by this paper
• Thrombin and fibrinolysis.

  2003influential reference
• Carboxypeptidase B inhibitors reduce tissue factor-induced renal microthrombi in rats.

  2003cited by this paper
• Risk of Ischemic Stroke Associated With Functional Thrombin-Activatable Fibrinolysis Inhibitor Plasma Levels

  2003cited by this paper
• Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris

  2003cited by this paper
• Thrombin‐activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system

  2003cited by this paper
• Molecular mechanisms of initiation of fibrinolysis by fibrin

  2003cited by this paper
• Development of a Genotype 325–Specific proCPU/TAFI ELISA

  2003cited by this paper
• Activated thrombin-activatable fibrinolysis inhibitor attenuates spontaneous fibrinolysis of batroxobin-induced fibrin deposition in rat lungs

  2003cited by this paper
• Local proCPU (TAFI) Activation during Thrombolytic Treatment in a Dog Model of Coronary Artery Thrombosis can be Inhibited with a Direct, Small Molecule Thrombin Inhibitor (Melagatran)

  2002cited by this paper
• Two Naturally Occurring Variants of TAFI (Thr-325 and Ile-325) Differ Substantially with Respect to Thermal Stability and Antifibrinolytic Activity of the Enzyme*

  2002cited by this paper
• Plasma Thrombin-Activatable Fibrinolysis Inhibitor Antigen Concentration and Genotype in Relation to Myocardial Infarction in the North and South of Europe

  2002cited by this paper
• Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life.

  2002cited by this paper
• Enhancement of Endogenous Plasminogen Activator-induced Thrombolysis by Argatroban and APC and Its Control by TAFI, Measured in An Arterial Thrombolysis Model In Vivo Using Rat Mesenteric Arterioles

  2002cited by this paper
• Elastase from Activated Human Neutrophils Activates Procarboxypeptidase R

  2002cited by this paper
• In vivo regulation of plasminogen function by plasma carboxypeptidase B.

  2002cited by this paper
• Immunological Assay for the Determination of Procarboxypeptidase U Antigen Levels in Human Plasma

  2001cited by this paper
• Human Thrombi Contain an Abundance of Active Thrombin

  2001cited by this paper
• Regulation of Fibrinolysis in Plasma by TAFI and Protein C Is Dependent on the Concentration of Thrombomodulin

  2001cited by this paper
• Fast Homogeneous Assay for Plasma Procarboxypeptidase U

  2001cited by this paper
• The Role of Protein S in the Activation of Thrombin Activatable Fibrinolysis Inhibitor (TAFI) and Regulation of Fibrinolysis

  2001cited by this paper
• Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled.

  2001cited by this paper
• A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels.

  2001cited by this paper
• Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis.

  2001cited by this paper
• Inactivation of Active Thrombin-activable Fibrinolysis Inhibitor Takes Place by a Process That Involves Conformational Instability Rather Than Proteolytic Cleavage*

  2000cited by this paper
• An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model.

  2000cited by this paper
• Proteolytic activation of purified human procarboxypeptidase U.

  2000cited by this paper
• Roles of Thermal Instability and Proteolytic Cleavage in Regulation of Activated Thrombin-activable Fibrinolysis Inhibitor*

  2000influential reference
• Elements of the Primary Structure of Thrombomodulin Required for Efficient Thrombin-activable Fibrinolysis Inhibitor Activation*

  2000cited by this paper
• High levels of coagulation factor XI as a risk factor for venous thrombosis

  2000cited by this paper
• The protein C pathway

  2000cited by this paper
• High levels of coagulation factor XI as a risk factor for venous thrombosis.

  2000cited by this paper
• Immunohistochemical localisation of carboxypeptidase U in human thrombi

  2000cited by this paper
• Thrombin-Activatable Fibrinolysis Inhibitor Antigen Levels and Cardiovascular Risk Factors

  2000cited by this paper
• Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis.

  2000cited by this paper
• Plasma TAFI Antigen Variations in Healthy Subjects

  2000cited by this paper
• Plasma Procarboxypeptidase U in Men with Symptomatic Coronary Artery Disease

  2000cited by this paper
• A novel approach to arterial thrombolysis.

  1999cited by this paper
• Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B).

  1999cited by this paper
• Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma.

  1999cited by this paper
• Characterization of Plasmin-mediated Activation of Plasma Procarboxypeptidase B

  1999cited by this paper
• A Novel Approach to Arterial Thrombolysis

  1999cited by this paper
• Plasma TAFI Levels Influence the Clot Lysis Time in Healthy Individuals in the Presence of an Intact Intrinsic Pathway of Coagulation

  1998cited by this paper
• Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors.

  1998cited by this paper
• Identification and Characterization of Two Thrombin-activatable Fibrinolysis Inhibitor Isoforms

  1998influential reference
• Thrombomodulin in Human Plasma Contributes to Inhibit Fibrinolysis through Acceleration of Thrombin-dependent Activation of Plasma Procarboxypeptidase B

  1998cited by this paper
• Plasma and Recombinant Thrombin-activable Fibrinolysis Inhibitor (TAFI) and Activated TAFI Compared with Respect to Glycosylation, Thrombin/Thrombomodulin-dependent Activation, Thermal Stability, and Enzymatic Properties*

  1998cited by this paper
• Human Procarboxypeptidase U, or Thrombin-activable Fibrinolysis Inhibitor, Is a Substrate for Transglutaminases

  1998cited by this paper
• Activation of Thrombin-activable Fibrinolysis Inhibitor Requires Epidermal Growth Factor-like Domain 3 of Thrombomodulin and Is Inhibited Competitively by Protein C*

  1998cited by this paper
• A Study of the Mechanism of Inhibition of Fibrinolysis by Activated Thrombin-activable Fibrinolysis Inhibitor*

  1998cited by this paper
• Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor.

  1998cited by this paper
• Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis.

  1997cited by this paper
• On the Mechanism of the Antifibrinolytic Activity of Plasma Carboxypeptidase B*

  1997cited by this paper
• Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary artery thrombolysis

  1997cited by this paper
• TAFI, or Plasma Procarboxypeptidase B, Couples the Coagulation and Fibrinolytic Cascades through the Thrombin-Thrombomodulin Complex*

  1996cited by this paper
• Structure and function of mammalian zinc carboxypeptidases

  1996cited by this paper
• The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent.

  1996cited by this paper
• An Antifibrinolytic Mechanism Describing the Prothrombotic Effect Associated with Factor VLeiden*

  1996cited by this paper
• The gene for human carboxypeptidase U (CPU)--a proposed novel regulator of plasminogen activation--maps to 13q14.11.

  1996cited by this paper
• Purification and Characterization of TAFI, a Thrombin-activable Fibrinolysis Inhibitor (*)

  1995cited by this paper
• Plasma carboxypeptidases as regulators of the plasminogen system.

  1995cited by this paper
• Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis.

  1995cited by this paper
• Activation and characterization of procarboxypeptidase B from human plasma.

  1995cited by this paper
• The specific roles of finger and kringle 2 domains of tissue-type plasminogen activator during in vitro fibrinolysis.

  1994cited by this paper
• Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen.

  1994influential reference
• The Role of Factor XI in Coagulation

  1993cited by this paper

• Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?

  2021cites this paper
• Characterization of TAFI Activation by the Thrombin-Thrombomodulin Complex

  2015cites this paper
• Thrombin-activatable fibrinolysis inhibitor is activated in an instant blood-mediated inflammatory reaction after intraportal islet transplant.

  2014cites this paper
• Polymorphism of thrombin‐activatable fibrinolysis inhibitor and risk of intracranial haemorrhage in factor XIII deficiency

  2014cites this paper
• ASSESSMENT OF RELATIONSHIP BETWEEN CENTRAL NERVOUS SYSTEM BLEEDING IN FACTOR XIII DEFICIENCY AND THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR POLYMORPHISM

  2013cites this paper
• Kinetic and proteomic identification of protease inhibitors in marine invertebrates. Characterization of a carboxypeptidase inhibitor isolated from the mollusc nerita versicolor

  2012cites this paper
• Thrombin-activatable fibrinolysis inhibitor is activated in vivo in a baboon model of Escherichia coli induced sepsis

  2012cites this paper
• Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinolysis and inflammation.

  2012cites this paper
• Measuring the mechanical properties of blood clots formed via the tissue factor pathway of coagulation.

  2012cites this paper
• Deciphering the molecular signaling cascade in neuronal death

  2011cites this paper
• Thrombin-activatable fibrinolysis inhibitor and bacterial infections

  2011cites this paper
• Insights into the molecular inactivation mechanism of human activated thrombin‐activatable fibrinolysis inhibitor

  2010cites this paper
• The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome

  2010cites this paper
• Fibrinolytic parameters in children with noncatheter thrombosis: a pilot study

  2010cites this paper
• Development of a sensitive and selective assay for the determination of procarboxypeptidase U (thrombin-activatable fibrinolysis inhibitor) in plasma.

  2010cites this paper
• The X‐Ray Structure of Carboxypeptidase A Inhibited by a Thiirane Mechanism‐Based Inhibitor

  2010cites this paper
• Total synthesis of (+/-)- and (-)-actinophyllic acid.

  2010cites this paper
• Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?

  2009cites this paper
• Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients.

  2009cites this paper
• Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia.

  2009cites this paper
• Thromboelastometry, a Possible Tool to Identify Women at Risk of Pregnancy Loss

  2009cites this paper
• The complexity of neurobiological processes in acute ischemic stroke.

  2009cites this paper
• Aromatic Organic Compounds as Scaffolds for Metallocarboxypeptidase Inhibitor Design

  2009cites this paper
• Thrombin-activatable fibrinolysis inhibitor polymorphisms and recurrent pregnancy loss.

  2009cites this paper
• Progress toward the total synthesis of (+/-)-actinophyllic acid.

  2009cites this paper
• A new type of five-membered heterocyclic inhibitors of basic metallocarboxypeptidases.

  2009cites this paper
• Procarboxypeptidase U (TAFI) and the Thr325Ile proCPU polymorphism in patients with hereditary mucocutaneous hemorrhages.

  2009cites this paper
• RARRES1 regulation of alpha-tubulin tyrosination, cytokinesis and vertebrate embryonic development

  2009cites this paper
• Discovery and characterization of small molecular weight metallocarboxypeptidase inhibitors

  2009cites this paper
• Comparative substrate specificity study of carboxypeptidase U (TAFIa) and carboxypeptidase N: development of highly selective CPU substrates as useful tools for assay development.

  2008cites this paper
• Structure of activated thrombin-activatable fibrinolysis inhibitor, a molecular link between coagulation and fibrinolysis.

  2008cites this paper
• On Diagnostic Procedures in Pulmonary Embolism

  2008cites this paper
• Structure and Mechanism of Metallocarboxypeptidases

  2008cites this paper
• The Crystal Structure of Thrombin-activable Fibrinolysis Inhibitor (TAFI) Provides the Structural Basis for Its Intrinsic Activity and the Short Half-life of TAFIa*♦

  2008cites this paper
• Carboxypeptidase U (TAFIa) activity is induced in vivo in ischemic stroke patients receiving thrombolytic therapy

  2007cites this paper
• Influence of the Thr325Ile polymorphism on procarboxypeptidase U (thrombin‐activable fibrinolysis inhibitor) activity‐based assays

  2007cites this paper
• Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis.

  2007cites this paper
• Effects of combined oral contraceptives on hemostasis and biochemical risk indicators for venous thromboembolism and atherothrombosis

  2007cites this paper